ArticleDermatology and therapy2026

Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.

Henner Zirpel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.